Dr Demos Katritsis and his writing group have produced an important new guidelines document on the management of all types of supraventricular tachycardias (SVTs). The one exception is atrial fibrillation (AF), which is covered in the 2016 European Society of Cardiology (ESC) AF guidelines. This document is a complete rewrite of the 2003 SVT guidelines, which were published as a joint document with the American Heart Association and the American College of Cardiology. In this brief article, I will highlight the most important features of the new 2019 ESC SVT Guidelines.
The first important change in the 2019 ESC SVT guideline, when compared with the prior guideline published 16 years earlier is that the Class and level of recommendations supporting catheter ablation for chronic treatment of all types of SVTs have been increased. This shift reflects the vast literature, and large and consistent worldwide experience supporting the curative role of catheter ablation for most types of SVT. Catheter ablation is now provided with a Class 1 level of evidence (LOE) A or B recommendation for nearly all SVTs. The most notable exceptions to this rule are inappropriate sinus tachycardia and multifocal atrial tachycardia, for which catheter ablation plays little to no role in management. Another exception is SVTs in patients with congenital heart disease, where catheter ablation in experienced centres is provided a 2A, LOE C recommendation.
Another important change reflects the role of pharmacologic therapy in SVT management. The document has downgraded the Class and LOE of recommendations for pharmacologic therapy of most types of SVTs. This shift reflects the remarkable paucity of data from clinical trials demonstrating the safety and efficacy of most antiarrhythmic agents, including beta-blockers, calcium channel blockers, digoxin, and also Class 1 and 3 antiarrhythmic agents. Oral disopyramide, procainamide, quinidine, and sotalol are not included in the document. The only recognized role of amiodarone is for acute management of wide complex tachycardia (Class 2b, LOE B), focal atrial tachycardia (Class 2b, LOE C), macro-reentrant atrial arrhythmias (Class 2b, LOE C), and antidromic atrioventricular reentrant tachycardia (Class 2b, LOE B). And the only recognized role for amiodarone for chronic SVT management is for treatment of patients with macro-reentrant atrial tachycardia (Class 2b, LOE C) and also for treatment of SVT in congenital heart disease patients when catheter ablation is not possible or successful (Class 2b, LOE C). Amiodarone is not listed as a chronic therapy for atrioventricular nodal reentrant tachycardia and receives a Class 2, LOE B recommendation for pre-excited AF.
A third important update in this new SVT guideline concerns the management of patients with asymptomatic pre-excitation. Since publication of the 2003 guidelines, there have been many studies which have provided new data to help guide evaluation and management of patients with asymptomatic pre-excitation. Based on these studies, it is now recommended that asymptomatic patients with pre-excitation who have high-risk occupations or are competitive athletes should undergo an electrophysiology study (EPS) with isoproterenol infusion for risk stratification (Class 1 <LOE B).
If a high-risk accessory pathway (AP) is identified, catheter ablation is recommended (Class 1, LOE B). For all patients, performing a risk stratifying EPS is given a Class 2a, LOE B recommendation. Non-invasive risk stratification is provided a 2b, LOE B recommendation. And if a non-low-risk AP is identified an EPS is recommended.
Another important new recommendation is that catheter ablation is recommended in a patient with reduced left ventricular function and asymptomatic pre-excitation that may cause ventricular dyssynchrony (e.g. a right-sided AP). Finally, this document also allows for catheter ablation of an AP in a patient with asymptomatic preexcitation and an EPS demonstrating low-risk properties (Class 2B, LOE C), based on the operator's experience and the patient's preferences.
A The Great Cardiovascular Quiz With prizes, quick-fire buzzer rounds, instant eliminations and a tricky question or two, the Great Cardiovascular Quiz brought a lively finale to day two of European Society of Cardiology (ESC) Congress 2019.
More Q-wave than QI, the emphasis was on topically challenging cardiovascular diagnostics and dilemmas, with the odd wildcard question thrown in to keep the heart rate of the contestants sufficiently high.
Quizmasters John-Paul Carpenter and Mark Westwood were supported by Omar Chehab, Debashish Das, Abhishek Joshi, and Filip Zemrak in presenting the contest, which saw the initial contestants of the whole audience slowly whittled down in number as the rounds progressed. Humour and music were in abundance during the hourlong quiz, which opened with Parisian sepia scenes from the 19th century and the inimitable sound of Edith Piaf. The musical repertoire later ranged from Led Zeppelin to clips from the Sound of Music, the famous Countdown clock and from Benny Hill's UK TV series of the 1970s.
Tongues were firmly in cheeks for Carpenter and Westwood, who could arguably claim to be the finest comedy-quiz double act in cardiology. But while it was all great fun, there were serious questions to answer across four rounds entitled Play Your Cards Right, Vote with Your Feet, Three Teams to One, and The Final Countdown.
There were also spot prizes ahead of the big prizes for the final three contestants-and these were ESC Professional Member membership (value 120 Euro) plus vouchers of 25 Euro for third place, 50
The Ten Commandments for 2019 ESC Guidelines on Supraventricular Arrhythmias
(1) Start with vagal manoeuvres and adenosine in the acute evaluation and management of patients with sustained forms of SVT.
(2) Supraventricular tachycardias may present as a wide complex tachycardia due to concomitant BBB, drug-induced conduction slowing, antegrade conduction of an AP, or an atrial sensed ventricular paced rhythm. Despite this fact, wide complex tachycardias should be considered to be caused by ventricular tachycardia until proved otherwise.
(3) Cardioversion is the preferred initial treatment strategy for SVT patients who are haemodynamically unstable.
(4) Catheter ablation is the preferred treatment strategy for almost all patients with symptomatic SVTs, with the exception of pregnant patients in the first trimester and also patients with inappropriate sinus tachycardia, postural orthostatic tachycardia syndrome, and multifocal atrial tachycardia. (5) Patients with both atrial flutter and AF should be anticoagulated according to the AF anticoagulation guidelines. Long-term anticoagulation in patients with atrial flutter alone, should be considered for anticoagulation but the threshold for initiation of anticoagulation has not been wellestablished. (6) Patients with asymptomatic pre-excitation who are competitive athletes should undergo EPS with isoproterenol for risk stratification. If a 'high risk' AP is identified catheter ablation is recommended. (7) Patients with pre-excitation who are asymptomatic and who are not competitive athletes may consider either an EPS for risk stratification (Class 2A, LOE B) , or non-invasive risk stratification (Class 2B, LOE C). (8) Catheter ablation can be considered for patients with asymptomatic pre-excitation who have 'low risk' APs provided the procedure is performed at an experienced centre and after careful consideration of the patient's preferences. (9) Avoid antiarrhythmic drugs during the first trimester of pregnancy. (10) Catheter ablation is recommended for treatment of patients with tachycardia-induced cardiomyopathy. 
